Successful Pembrolizumab Rechallenge in a Patient With Advanced NSCLC After Pemetrexed-Induced Palm Pustules

We previously reported the case of a 69-year-old man with advanced NSCLC who was treated with a combination of pembrolizumab, carboplatin, and pemetrexed, which had induced palm pustules. 1 Nakashima K. Tsubata Y. Niihara H. Araki A. Isobe T. Palm pustules induced by pemetrexed. J Thorac Oncol. 2021; 16: 1589-1591 Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar Palm Pustules Induced by PemetrexedJournal of Thoracic OncologyVol. 16Issue 9PreviewA 69-year-old man with recurrent postoperative lung adenocarcinoma (negative for EGFR mutation and ALK rearrangement) was administered a combination therapy of pembrolizumab, carboplatin, and pemetrexed every 3 weeks. He received four cycles of induction treatment and one cycle of maintenance treatment with pembrolizumab and pemetrexed. Dexamethasone (9.9 mg for induction treatment and 6.6 mg for maintenance treatment) was used only on day 1 of each cycle because he had poorly controlled diabetes mellitus. Full-Text PDF Open Access